Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: Tinzaparin in lung tumours;Effet de la tinzaparine sur la mortalité du cancer bronchique non à petites cellules opéré

Revue des Maladies Respiratoires

Volumn 28, Issue 5, 2011, Pages 654-659

  Meyer, G ^a   Besse, B ^b   Friard, S ^c   Girard, P ^d   Corbi, P ^e   Azarian, R ^f   Monnet, I ^g   Alifano, M ^h   Chouaid, C ⁱ   Descourt, R ^j   Dennewald, G ^k   Taillade, L ^l   De Luca, K ^m   Giraud, F ^h   Pichon, E ⁿ   Chatellier, G ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c FOCH HOSPITAL   (France)

^d INSTITUT MUTUALISTE MONTSOURIS   (France)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^h HÔTEL DIEU   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j BREST UNIVERSITY HOSPITAL   (France)

^k CENTRE CARDIOLOGIQUE DU NORD   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m Centre Spécialisé en Pneumologie   (France)

ⁿ UNIVERSITY HOSPITAL OF TOURS   (France)

more..

Author keywords

Adjuvant therapy; Heparin; Non small cell lung cancer; Survival; Tinzaparin

Indexed keywords

TINZAPARIN;

ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFORMED CONSENT; LUNG NEOPLASMS; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; PNEUMONECTOMY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; VENOUS THROMBOSIS;

EID: 79959629149     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2011.03.015     Document Type: Article

References (20)

1. M. Hejna M. Raderer C.C. Zielinski Inhibition of metastases by anticoagulants J Natl Cancer Inst 91 1999 22 36 (Pubitemid 29042440)
2. S.A. Mousa S. Mohamed Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy Oncol Rep 12 2004 683 688
3. L.R. Zacharski D.L. Ornstein Heparin and cancer Thromb Haemost 80 1998 10 23 (Pubitemid 28353491)
4. G. Agnelli Venous thromboembolism and cancer: a two-way clinical association Thromb Haemost 78 1997 117 120 (Pubitemid 27289227)
5. F.R. Rickles S. Patierno P.M. Fernandez Tissue factor, thrombin, and cancer Chest 124 2003 58S 68S (Pubitemid 37128437)
6. M.L. Nierodzik F. Kajumo S. Karpatkin Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo Cancer Res 52 1992 3267 3272
7. M.L. Nierodzik A. Plotkin F. Kajumo, et al. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo J Clin Invest 87 1991 229 236
8. J.A. Nagy L.F. Brown D.R. Senger, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition Biochim Biophys Acta 948 1989 305 326 (Pubitemid 19055388)
9. L. Borsig R. Wong J. Feramisco, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis Proc Natl Acad Sci U.S.A. 98 2001 3352 3357 (Pubitemid 32220849)
10. S.A. Mousa S. Mohamed Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor Thromb Haemost 92 2004 627 633 (Pubitemid 39248021)
11. J.L. Stevenson S.H. Choi A. Varki Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity Clin Cancer Res 11 2005 7003 7011 (Pubitemid 41428760)
12. R.J. Ludwig B. Boehme M. Podda, et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis Cancer Res 64 2004 2743 2750 (Pubitemid 38500611)
13. J.L. Stevenson A. Varki L. Borsig Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects Thromb Res 120 2007 S107 S111
14. M.K. Gould A.D. Dembitzer R.L. Doyle, et al. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials Ann Intern Med 130 1999 800 809 (Pubitemid 29231148)
15. D. Green R.D. Hull R. Brant, et al. Lower mortality in cancer patients treated with low molecular weight versus standard heparin Lancet 339 1992 1476
16. N.M. Kuderer T.L. Ortel C.W. Francis Impact of venous thromboembolism and anticoagulation on cancer and cancer survival J Clin Oncol 27 2009 4902 4911
17. R. Arriagada B. Bergman A. Dunant, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360 (Pubitemid 38101630)
18. J.P. Pignon H. Tribodet G.V. Scagliotti, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 2008 3552 3559
19. P. Goldstraw J. Crowley K. Chansky, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 2007 706 714 (Pubitemid 47357522)
20. P. Mismetti J.M. Baud F. Becker, et al. Recommandations de bonne pratique : prevention et traitement de la maladie thromboembolique veineuse en medecine J Mal Vasc 35 2010 127 136